Scinai Immunotherapeutics (SCNI) EBITDA (2015 - 2026)

Scinai Immunotherapeutics has disclosed EBITDA across 12 years of filings, most recently posting -$2.1 million for Q2 2026.

• In Q2 2026, EBITDA rose 2.23% year-over-year to -$2.1 million; the TTM figure through Jun 2026 stood at -$8.4 million (up 0.83% YoY), while the FY2025 annual figure was -$9.7 million, down 12.82% from the prior year.
• EBITDA came in at -$2.1 million for Q2 2026 at Scinai Immunotherapeutics, up from -$2.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $3.2 million in Q1 2023 to a low of -$5.9 million in Q2 2024.
• Average EBITDA over 5 years is -$1.3 million, with a median of -$2.2 million recorded in 2025.
• The largest YoY upside for EBITDA was 221.84% in 2023 against a maximum downside of 197.27% in 2023.
• Over 5 years, EBITDA stood at $3.0 million in 2022, then tumbled by 160.32% to -$1.8 million in 2023, then retreated by 24.14% to -$2.3 million in 2024, then grew by 3.0% to -$2.2 million in 2025, then climbed by 2.23% to -$2.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$2.1 million in Q2 2026, -$2.5 million in Q1 2026, and -$2.2 million in Q2 2025.